Related Experiment Video

Updated: Aug 24, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

New antiepileptic agents

Linda P Nelson1, Ilse Savelli-Castillo

  • 1Department of Pediatric Dentistry, Children 's Hospital, Boston, Mass, USA.

Pediatric Dentistry
|April 15, 2004
PubMed

Insights

Seven new antiepileptic drugs (AEDs) approved since 1993 offer improved treatment for refractory childhood epilepsy. These medications provide better outcomes for about 25% of pediatric patients previously unresponsive to traditional therapies.

Area of Science:

  • Neurology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Epilepsy treatment in children has seen limited advancements for many years.
  • The US Food and Drug Administration (FDA) has approved new antiepileptic drugs (AEDs) starting in 1993.
  • A significant portion of pediatric patients remain refractory to conventional antiepileptic drug therapies.

Purpose of the Study:

  • To provide an update on new antiepileptic drugs (AEDs) for the pediatric population.
  • To summarize the efficacy and side effects of newly approved AEDs in children.
  • To inform pediatric dentists about advancements in childhood epilepsy treatment.

Main Methods:

  • Review of recent US FDA approvals for antiepileptic drugs (AEDs).
  • Summary of available information on the efficacy of new AEDs in pediatric patients.
  • Compilation of data on the side effect profiles of these new AEDs in children.

Main Results:

  • Seven new AEDs have been introduced in the United States since 1993.
  • These new AEDs offer more successful treatment outcomes for approximately 25% of pediatric patients with refractory epilepsy.
  • The new AEDs include felbamate, gabapentin, lamotrigine, topiramate, tiagabine, vigabatrin, and oxcarbazepine.

Conclusions:

  • Recent FDA-approved AEDs represent a significant therapeutic improvement for childhood epilepsy.
  • Newer antiepileptic drugs provide viable options for pediatric patients who do not respond to older medications.
  • Understanding the efficacy and side effects of these AEDs is crucial for managing pediatric epilepsy.

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...